Absci (ABSI) Hisse Özeti
Klinik aşamada bir biyofarmasötik şirketi olan Absci Corporation, Amerika Birleşik Devletleri'nde çeşitli antikor terapötikleri geliştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
ABSI Community Fair Values
Create NarrativeSee what 40 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Absci Corporation Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$11.11 |
| 52 Haftanın En Yüksek Seviyesi | US$12.06 |
| 52 Haftanın En Düşük Seviyesi | US$2.24 |
| Beta | 2.46 |
| 1 Aylık Değişim | 70.40% |
| 3 Aylık Değişim | 263.07% |
| 1 Yıllık Değişim | 313.01% |
| 3 Yıllık Değişim | 616.77% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | -48.54% |
Son Haberler & Güncellemeler
Recent updates
ABSI: Interim Hair Loss Data And Financing Will Drive Repricing Ahead
Absci's updated analyst price target now reflects a move from $8.11 to $12.40, with analysts pointing to positive interim ABS-201 data, expanded indications such as endometriosis, and reduced near term balance sheet risk as key drivers of their revised valuation work. Analyst Commentary Analyst commentary on Absci centers on how far the ABS-201 program and the broader AI-driven platform can carry the valuation, with price targets across the Street now clustered well above prior levels.Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain
Summary Absci Corporation stock surged over 30% after announcing a $100M equity offering with Eli Lilly as a key participant. ABSI's AI-designed antibody ABS-201 targets androgenetic alopecia and endometriosis, with promising Phase 1 safety and PK data but no human proof-of-concept yet. Despite ABSI management's $4.5B peak sales projection for ABS-201, I maintain a Hold rating due to early-stage risk and limited in-human efficacy data. Upcoming Phase II readouts for ABS-201 in AGA and endometriosis within 24 months present significant catalysts, but the investment remains speculative. Read the full article on Seeking AlphaAbsci (ABSI) Stock Could Be 63% Overvalued After Leerink Starts Coverage
Absci (ABSI) drew fresh attention after Leerink initiated coverage, highlighting the company’s AI native, clinical stage drug pipeline, including ABS-20 and ABS-201, and pointing to 2026 as a potentially important clinical data year. See our latest analysis for Absci. Absci’s recent coverage has coincided with strong momentum, with a 30 day share price return of 60.04% and a 90 day share price return of 150.34%. The 1 year total shareholder return of 169.45% points to strong longer term...We Think Absci (NASDAQ:ABSI) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Does Absci (NASDAQ:ABSI) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
Summary Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI’s AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differentiated from other competitors. ABSI trades at a cheap P/B of 1.5, so I don’t think the shares have priced in the potential of its partnership with AMD yet. My main concern is that ABSI operates with highly speculative technologies, and its candidates remain in the early R&D stages. Read the full article on Seeking AlphaAbsci Corporation: Struggling To Live Up To Its AI Promise
Summary Absci Corporation's stock has rebounded due to new collaborations, but skepticism about AI's impact on drug discovery keeps it heavily underwater from its IPO price. Absci uses AI and wet lab technologies to speed up drug discovery, aiming to reduce preclinical periods to under two years. Despite partnerships with Merck, AstraZeneca, and others, Absci's revenue remains minimal, and it has no advanced pipeline assets yet. With a market cap just over $300 million and cash runway into 1H27, Absci is a speculative play in the AI drug discovery space. An analysis around Absci Corporation follows in the paragraphs below. Read the full article on Seeking AlphaIs Absci (NASDAQ:ABSI) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Absci: Embryonic Pipeline Looks Expensive Relative To Peers
Summary Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its approach though. While cash burn is currently limited, Absci's operations are ramping, meaning increased costs could begin to pressure the share price in the future. Absci has largely avoided the growing pessimism towards AI-enabled drug discovery companies and is beginning to look expensive relative to peers as a result. Read the full article on Seeking AlphaAbsci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Summary Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033. The ulcerative colitis treatment market is expected to reach $14.77 billion by 2033. Read the full article on Seeking AlphaAbsci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
Summary Absci Corporation uses IDCP technology to quickly produce high-quality drug candidates in as little as six weeks, reducing costs and improving research success rates. The company has promising candidates in inflammatory bowel disease, dermatology, and immuno-oncology, attracting major partnerships with over $900 million in deal value and royalties. ABSI focuses on three therapeutic areas: inflammatory bowel disease, dermatology, and immuno-oncology. Investors should be aware of the high risks due to the speculative nature of AI-driven drug discovery and potential funding needs. Still, ABSI trades at a reasonable valuation, making it a sound speculative "buy" for investors aware of biotech's inherent risks. Read the full article on Seeking AlphaIs Absci (NASDAQ:ABSI) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula
Summary Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July 2021. Nearly all AI-driven drug discovery companies have struggled with overall share price performance since IPO. Absci's stock has been picking up - +250% across the past six months - thanks to investment in the sector, and a recently agreed partnership with AstraZeneca. Merck is another Big Pharma partner, but these deals don't guarantee revenues and with development programs preclinical, it's difficult to assign much value. Without its "AI" tag, Absci would likely be a $100m - $200m market cap valuation company. The company may show its mettle in time, but the prospect of near term revenues, or further upside, seems remote in 2024. Read the full article on Seeking AlphaAbsci: Differentiated Antibody Discovery Play
Summary Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual goal of in silico drug design. While Absci's stock has benefitted from AI hype in recent months, the company has substance. Its approach to antibody drug development is unique and could have advantages. Absci's valuation is still reasonable given the company's long-term potential, but the stock price is likely to be tied to AI sentiment in the near term, creating downside risk. Read the full article on Seeking AlphaHissedar Getirileri
| ABSI | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 10.3% | 3.7% | 1.6% |
| 1Y | 313.0% | 37.9% | 21.1% |
Getiri vs. Endüstri: ABSI geçen yıl % 37.9 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: ABSI geçen yıl % 21.1 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| ABSI volatility | |
|---|---|
| ABSI Average Weekly Movement | 18.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: ABSI hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: ABSI 'nin haftalık oynaklığı ( 19% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2011 | 140 | Sean McClain | www.absci.com |
Klinik aşamada bir biyofarmasötik şirketi olan Absci Corporation, Amerika Birleşik Devletleri'nde çeşitli antikor terapötikleri geliştirmektedir. Klinik öncesi geliştirme programları arasında enflamatuar bağırsak hastalığının tedavisi için Faz 1 klinik çalışmasında olan ABS-101; androjenik alopesi tedavisi için faz 1/2a klinik çalışmasında olan bir anti-prolaktin reseptör (PRLR) antikoru olan ABS-201; immüno-onkoloji tedavisi için ABS-301; ve onkoloji tedavisi için ABS-501 bulunmaktadır. Absci Corporation'ın PrecisionLife, Memorial Sloan Kettering Kanser Merkezi, Twist Bioscience, Owkin, Oracle Corporation ve Advanced Micro Devices, Inc. ile ortak araştırma ve geliştirme faaliyetleri için işbirliği anlaşmaları bulunmaktadır.
Absci Corporation Temel Bilgiler Özeti
| ABSI temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.96b |
| Kazançlar(TTM) | -US$118.44m |
| Gelir(TTM) | US$1.84m |
ABSI aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ABSI gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.84m |
| Gelir Maliyeti | US$83.63m |
| Brüt Kâr | -US$81.79m |
| Diğer Giderler | US$36.64m |
| Kazançlar | -US$118.44m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.70 |
| Brüt Marj | -4,454.96% |
| Net Kâr Marjı | -6,450.76% |
| Borç/Özkaynak Oranı | 0.2% |
ABSI uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/01 14:05 |
| Gün Sonu Hisse Fiyatı | 2026/07/01 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Absci Corporation 15 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Ryskin | BofA Global Research |
| Kambiz Yazdi | BTIG |
| Vamil Divan | Guggenheim Securities, LLC |